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The extracellular signal-regulated kinases (ERKs) are key components of multiple important
cell signaling pathways regulating diverse biological responses. This signaling is character-
ized by phosphorylation cascades leading to ERK1/2 activation and promoted by various
cell surface receptors including G protein-coupled receptors (GPCRs) and receptor tyro-
sine kinases (RTKs). We report the development of a new cell-based Phospho-ERK1/2
assay (designated Phospho-ERK), which is a sandwich proximity-based assay using the
homogeneous time-resolved fluorescence technology. We have validated the assay on
endogenously expressed ERK1/2 activated by the epidermal growth factor as a prototypi-
cal RTK, as well as various GPCRs belonging to different classes and coupling to different
heterotrimeric G proteins.The assay was successfully miniaturized in 384-well plates using
various cell lines endogenously, transiently, or stably expressing the different receptors.
The validation was performed for agonists, antagonists, and inhibitors in dose–response
as well as kinetic analysis, and the signaling and pharmacological properties of the differ-
ent receptors were reproduced. Furthermore, the determination of a Z ′-factor value of 0.7
indicates the potential of the Phospho-ERK assay for high-throughput screening of com-
pounds that may modulate ERK1/2 signaling. Finally, our study is of great interest in the
current context of investigating ERK1/2 signaling with respect to the emerging concepts of
biased ligands, G protein-dependent/independent ERK1/2 activation, and functional trans-
activation between GPCRs and RTKs, illustrating the importance of considering the ERK1/2
pathway in cell signaling
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INTRODUCTION
The activation of mitogen-activated protein kinases (MAPKs)
constitutes one of the major intracellular signaling pathways that
couples signals from cell surface receptors, such as receptor tyro-
sine kinases (RTKs) and G protein-coupled receptors (GPCRs),
to gene expression regulation and other intracellular events (1–
6). Indeed, following stimulation, these receptors promote a
Abbreviations: AngII, angiotensin II; AT1R, angiotensin II type 1 receptor;
AVP, arginine-vasopressin peptide; cAMP, cyclic adenosine mono-phosphate; CB1,
cannabinoid receptor 1; CHO, Chinese hamster ovary; DAMGO, Tyr-Ala-Gly-
N -methyl-Phe-Gly-ol; EGF, epidermal growth factor; EGFR, epidermal growth
factor receptor; ELISA, enzyme-linked immunosorbent assay; ERK, the extracel-
lular signal-regulated kinase; FRET, fluorescence resonance energy transfer; GPCR,
G protein-coupled receptors; HEK293, human embryonic kidney 293 cells; HTRF,
homogenous time-resolved fluorescence; HTS, high-throughput screening; MCP-
1, monocyte chemoattractant protein 1; MIP1β, macrophage inflammatory protein
1β; MOP3R,µ-opioid receptor 3; NMU2R, neuromedin receptor 2; PAR1, protease-
activated receptor 1; PGE2, prostaglandin E2; PTX, pertussis toxin; RTK, receptor
tyrosine kinase; S1P5, sphingosine-1-phosphate receptor 5; SDF1α, stromal cell-
derived factor 1α; V2R, vasopressin V2 receptor VIP, vasoactive intestinal peptide;
VPAC1, Vasoactive intestinal polypeptide receptor 1.
sequential protein kinase cascade (involving MAP4Ks, MAP3Ks,
and MAP2Ks) leading to the activation of ERKs (mostly ERK1/2,
also called p44/p42 MAPK) by MAP2K members (also called
MEKs) (5, 7, 8). In this cascade, MEK1/2 is phosphorylated and
activated by the Ras/Raf pathway and other MAP kinase kinase
kinases (MAP3Ks) through serine phosphorylation at the typi-
cal Ser-Xaa-Ala-Xaa-Ser/Thr motif in their activation loop (serine
218 and 222 for MEK1) (8, 9). Then, the activation of the ERK1/2
occurs by phosphorylation of both threonine and tyrosine residues
in the Thr-Glu-Tyr motif in their activation loop (Threonine
202/Tyrosine 204 for ERK1 and Threonine 185 and Tyrosine 187
for ERK2) (8, 10). The activation of the ERK1/2 pathway leads to
the modulation of diverse downstream transcription factors (NF-
κB, CREB, AP-1, and c-Myc) controlling the expression of the key
genes involved in the control of cell division, differentiation and
apoptosis (11).
Therefore, the development of a robust, highly sensitive and
specific assay to investigate the activation of ERK1/2 is of
great interest for both academic and industry researchers and
laboratories. Indeed, for many years the most useful and widely
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utilized method to investigate the ERK1/2 pathway has been based
on SDS-PAGE followed by Western blot using anti-Phospho-
ERK1/2 antibodies. Even though successful and reproducible, this
method has the considerable limitation of being time-consuming,
since protein extraction, electrophoresis, protein transfer, and then
overnight antibody incubation are required. In addition, western
blot analysis is not always quantitative, impairing applicability to
high-throughput screening (HTS), and drug profiling programs.
Alternative recent techniques have been proposed and developed
(12), such as the enzyme-linked immunosorbent assay (ELISA),
the Meso-Scale Assay electrochemiluminescence-based method
(13), the LICOR infrared fluorescence-based method (14), and
TGR BioSciences’ SureFire® assay that uses the AlphaScreen™
technology (PerkinElmer) (15, 16). These have been reviewed col-
lectively (17). Recently, a BRET-based ERK biosensor has also been
developed to temporally and spatially assess ERK activation (18).
Here, we describe a homogeneous time-resolved fluorescence
(HTRF®) cell-based assay compatible with HTS to investigate the
intracellular ERK1/2 signaling pathway. HTRF® combines fluo-
rescence resonance energy transfer (FRET) technology with time-
resolved (TR) measurement (19, 20). Since its development, this
technology has been applied to many antibody-based assays (19),
including second messengers (cAMP and IP-One) (21–24), kinases
(25), oligomerization of GPCRs (26, 27) and RTKs (28), G pro-
tein activation and β-arrestin recruitment (29), ligand-receptor
binding (30, 31), cytokines and biomarkers (32), and protein–
DNA/RNA interactions (33), and recently ERK1/2 with the
calcium-sensing receptor (22). The Phospho-ERK assay has been
validated using the two major cell surface receptor families, RTKs
and GPCRs, where both agonist-induced ERK1/2 phosphoryla-
tion and inhibition by receptor-selective inhibitors/antagonists as
well as the comparison with the classical western blot technique
were investigated in cell lines endogenously, transiently, or stably
expressing the different receptors.
MATERIALS AND METHODS
CELL LINES, PLASMIDS, AND REAGENTS
We used the HTRF® Phospho-ERK kit (Catalog number
64ERKPEG) recently launched by Cisbio Bioassays. Chinese ham-
ster ovary (CHO) cells stably expressing the different GPCRs were
generated by Euroscreen (Gosselies, Belgium), except the CHO–
muscarinic M1 receptor (M1) cell line that was kindly provided
by Dr. Denis Servent (CEA–DSV, Saclay, France). NIH-3T3, A431,
HEK293, HeLa, and SKOV3 cell lines were from American Type
Culture Collection (Manassas, VA, USA). HEK293FT cells were
from Life Technologies (Burwood, VIC, Australia). All the plas-
mids coding for the GPCRs used in Figure 4 were generated and/or
purchased by Kevin D. G. Pfleger’s laboratory from Missouri S&T
cDNA Resource Center1 and AT1R and NMU2R plasmids were
gifts from Prof. Walter Thomas (University of Queensland, Aus-
tralia) and Dr. Gary B. Willars (University of Leicester,UK), respec-
tively. All the agonists (EGF, MCP-1, MIP1β, SDF1α, DAMGO,
Endorphin-2, Norepinephrine, Isoproterenol, ACEA, PGE2, ITAC,
FTY720, VIP, arginine-vasopressin (AVP), carbachol, Ang II, and
1http://www.cdna.org
human Neuromedin U-25), the antagonist CTOP and Pertussis
toxin were from Sigma. The anti-Phospho-ERK1/2 antibody used
for western blot was purchased from Cell Signaling Technology.
CELL CULTURE AND TRANSIENT TRANSFECTIONS
Cells were maintained at 37°C, 5% CO2 in Complete Media (Dul-
becco’s modified Eagle’s medium containing 0.3 mg/ml glutamine,
100 IU/ml penicillin, and 100 mg/ml streptomycin; Gibco) supple-
mented with 10% fetal calf serum (FCS). Transient transfections
were carried out using Lipofectamine 2000 (Invitrogen) or Gene-
Juice (Novagen) according to manufacturer’s instructions. Cells
were harvested with 0.05% Trypsin–EDTA (Gibco).
ONE-PLATE PROTOCOL OF THE PHOSPHO-ERK ASSAY
Cells endogenously, transiently, or stably expressing the different
receptors were cultured overnight in a 384-well white plate (5000
cells/well) using 8µl of medium/well. Then 4µl/well of the 1×
stimulation buffer, containing or not the different agonists at the
different concentrations as indicated, were added to the cells. After
incubation at room temperature, cells were lysed by adding to
the stimulation mix 4µl/well of the supplemented lysis buffer,
followed by incubation for 30–45 min at room temperature with
shaking. Then 2µl of anti-ERK1/2-Europium/Terbium Cryptate
and 2µl of anti-Phospho-ERK1/2-d2 antibody solutions prepared
in the detection buffer were added. The plate was then incubated
for at least 2 h at room temperature before reading the fluores-
cence emission at 620 and 665 nm using either a Tecan Infinite
500 (Tecan Group Ltd.) or RUBYstar or PHERAstar FS plate reader
(BMG Labtech).
TWO-PLATE PROTOCOL OF THE PHOSPHO-ERK ASSAY
Cells endogenously, transiently, or stably expressing the differ-
ent receptors were cultured in a 96-well cell culture plate (5–
10× 104 cells/well, which corresponds roughly to 25µg of pro-
teins). Twenty-four hours after cell transfection, cells were starved
overnight in DMEM-serum free medium and then incubated in a
total volume of 50µl/well of the 1× stimulation buffer, containing
or not the different agonists at the different concentrations as indi-
cated. Cells were incubated at room temperature before the stim-
ulation mix was removed and cells were then lysed in 50µl/well
of the supplemented lysis buffer for 30–45 min at room tempera-
ture with shaking. Then 16µl of each lysate was transferred into
a 384-well small volume white plate and made up to the final vol-
ume of 20µl/well with 2µl of anti-ERK1/2-Europium/Terbium
Cryptate and 2µl of anti-Phospho-ERK1/2-d2 antibody solutions
prepared in the detection buffer. The plate was then incubated for
2 h at room temperature before reading the fluorescence emission
at 620 and 665 nm using a Tecan Infinite 500 (Tecan Group Ltd.),
RUBYstar, or PHERAstar FS plate reader (BMG Labtech), or an
EnVision 2102 plate reader (PerkinElmer).
COMPARISON BETWEEN HTRF®-BASED PHOSPHO-ERK ASSAY AND
WESTERN BLOT
A431 cells were seeded in 175 cm2 flasks. After 48 h incubation,
cells were washed with 10 ml PBS and then stimulated for 5 min
with 5 ml of EGF diluted at 100 nM in serum free medium. After
stimulation, cells were washed with 10 ml PBS and then lysed with
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FIGURE 1 | Principle of the Phospho-ERK assay. (A) Principle of
HTRF®-based ERK1/2 assay that consists of three experimental steps:
activation, cell lysis, and HTRF detection to quantify the total ERK1/2 as
well as the phosphorylation of ERK1/2 mediated by the major cell
surface receptors. This straightforward assay has been developed with
two different protocols: (B) the one-plate protocol where all the assay
steps are performed in the total volume of 20µl using one 384-well
small volume plate, and (C) the two-plate protocol in which the
stimulation and lysis steps are performed in the total volume of 50µl
using the initial 96-well plate containing the cells, then the cell lysate is
transferred into a 384-well small volume plate for HTRF detection after
addition of HTRF conjugated-antibodies as described in Section
“Materials and Methods” (Adapted from the CisBio Bioassays
website2 with permission).
3 ml of 1×HTRF complete lysis buffer for 30 min at room temper-
ature. Following centrifugation, the supernatant was collected, and
serial dilutions of lysates (1:2) were performed in 1×HTRF com-
plete lysis buffer. For the HTRF assay, 16µl of each diluted sample
was dispensed in a white 384-well small volume plate and detection
was performed as described in the following section. For western
blot analysis, 16µl of each diluted sample was denatured with
Laemmeli buffer and proteins were separated on a polyacrylamide
gel (NuPAGE Novex 4–12% Bis–Tris Gel). After electrotransfer,
PVDF membranes were blocked in 5% non-fat dry milk in Tris-
Buffered Saline – 0.1% Tween-20 (TBS-T). After washing steps,
2http://www.htrf.com
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FIGURE 2 | EGF-promoted Phospho-ERK1/2 activation detected by
the Phospho-ERK assay. (A)Total ERK levels quantified in various cell
lines. (B) Kinetics of EGF-induced ERK1/2 activation in HEK293 cells
endogenously expressing EGFR upon their stimulation with 100 nM of
EGF. (C,D)The effect of cell density on the phosphorylation of ERK1/2 (C)
versus total ERK1/2 (D) upon stimulation with increasing concentrations of
EGF as indicated. EGF-induced Phospho-ERK1/2 in various cell lines
endogenously expressing EGFR: NIH-3T3 (E), SKOV3 (F), and HEK293 (G)
cells (105 cells/well) stimulated for 5 min with increasing concentrations of
EGF before HTRF measurements were performed using the one-plate
protocol. The data are mean±SEM of three independent experiments
performed in duplicate.
membranes were incubated with anti-Phospho-ERK1/2 or anti-
total ERK antibodies, diluted at 1µg/ml in TBS-T with 5% Bovine
Serum Albumin (BSA). After overnight incubation at 4°C under
gentle agitation, membranes were washed three times with TBS-T,
and incubated with HRP-conjugated secondary antibody. After
1 h incubation at room temperature, membranes were washed
four times with TBS-T and incubated with SuperSignal West
Femto Chemiluminescent Substrate for 5 min at room tempera-
ture. Chemiluminescent signal was acquired on a G:BOX imaging
system (Syngene, Cambridge, UK).
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FIGURE 3 | Comparison of the Phospho-ERK and western blot assays,
and effect of cell density. A431 cells were used for the detection of the
phosphorylation of ERK1/2 upon cell stimulation with 100 nM of EGF for 5 min
(A) as well as the corresponding total ERK levels using the one-plate protocol
(B). S/N represents the signal-to-noise ratio through the different cell
densities. For this, serial dilutions of whole cells or cell lysate were dispensed
as indicated and analyzed side-by-side using the HTRF assay [top of (A,B)] and
western blot [bottom of (A,B)] as described in Section “Materials and
Methods.” (C)The detection limit of the total ERK levels using the two
methods was represented by plotting the total HTRF signals (HTRF) with the
enhanced chemiluminescence (ECL) signal obtained by densitometry from
the western blot (WB) normalized to the signal obtained with 60,000
cells/well as 100%. The data are mean±SEM of three independent
experiments performed in duplicate.
DATA PRESENTATION AND ANALYSIS
Data are presented as HTRF ratios, which are calculated as the
ratio between the emission at 665 nm and the emission at 620 nm
(×10,000). The sigmoidal curves were fitted to the dose–response
data using non-linear regression [Log (ligand) versus HTRF ratio]
by Prism 5 graphing software (GraphPad, La Jolla, CA, USA).
RESULTS AND DISCUSSION
In this study, we have reported validation of the HTRF®-based
Phospho-ERK assay to investigate the intracellular ERK1/2 signal-
ing pathway, compatible with HTS in 96-well and 384-well plate
formats. Epidermal growth factor receptor (EGFR) as a prototyp-
ical RTK and various GPCRs were tested in endogenous, stable,
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FIGURE 4 | GPCR-mediated Phospho-ERK1/2 monitored by the
Phospho-ERK assay. HEK293 cells (105 cells/well) transiently expressing
the different GPCRs indicated were used for the Phospho-ERK1/2 assay
under basal conditions or upon cell stimulation at different time points
(A,B) or 5 min (C,D) with 100 nM of the GPCR-specific agonists: AVP for
V2R, thrombin (1 U/ml) for PAR1, MCP-1 for CCR2, MIP1β for CCR5, IL-8
for CXCR2, SDF1α for CXCR4, Norepinephrine for α1aAR, Isoproterenol for
β2AR, and AngII for AT1R. Phospho-ERK1/2 detection was performed
using the two-plate protocol, which included the additional measurement
of high and low controls instead of the cell lysate. The data are
mean±SEM of three independent experiments performed in duplicate
(A–C) or represented as fold increase in Phospho-ERK1/2 over basal and
the resultant values are mean±SEM of three independent experiments
performed in triplicate (D).
and transient expression models. The assay has been validated
by studying multiple aspects including kinetics, dose-dependent
effects of agonists and inhibitors, phosphorylated versus total
ERK1/2, and the implication of heterotrimeric G proteins.
PRINCIPLE OF HTRF®-BASED PHOSPHO-ERK1/2 ASSAY (PHOSPHO-ERK
ASSAY)
Phospho-ERK is an in vitro assay developed to assess the phos-
phorylation of ERK1/2, a fingerprint of the MAP kinase signaling
pathway promoted by a variety of cell surface receptor families
such as GPCRs and RTKs. The assay is a sandwich immunoas-
say comprising three straightforward steps: (i) cell activation, (ii)
cell lysis, and (iii) detection of HTRF signals (Figure 1A). The
detection of HTRF signals is based on the incubation of the
cell lysate with an anti-ERK1/2 antibody labeled with Europium
cryptate that recognizes all ERK1/2 proteins, combined with either
an anti-ERK1/2 antibody (for the unphosphorylated forms) or
anti-Phospho-ERK1/2 antibody (for the phosphorylated forms)
labeled with d2 (Figure 1A). The proximity generated by the
simultaneous binding of the two antibodies leads to an effi-
cient FRET between the europium cryptate and the sensitized
acceptor, d2. The resulting acceptor emission at 665 nm is then
used as the assay readout. We have validated the assay using
two different protocols, one-plate (Figure 1B), and two-plate
(Figure 1C) protocols, as described in Section “Materials and
Methods.”
USE OF THE PHOSPHO-ERK ASSAY TO MONITOR EGFR-MEDIATED
ERK1/2 ACTIVATION
First, we quantified the total ERK1/2 levels in various cell lines
using our HTRF-based assay and as shown in Figure 2A. Posi-
tive and specific HTRF signals reflecting the total ERK1/2 were
measured and the signal varied with the cell line used. Then,
we assessed the kinetics of ERK1/2 phosphorylation mediated
by EGFR endogenously expressed in HEK293 cells. As shown
in Figure 2B, stimulation with 100 nM EGF showed a maximal
level of ERK1/2 phosphorylation at 2–5 min of stimulation, which
had largely disappeared after 10 min. The transient EGF-induced
ERK1/2 activation is consistent with many previous studies using
different cell lines (34–36). Consequently, all the data on EGFR
presented below have been generated at 5 min of stimulation
with EGF. Next, we examined the effect of cell density on EGF-
induced HTRF signals in the epidermal carcinoma-derived cell
line A431 known as a good cell model for the study of endoge-
nous EGFR activation and signaling. As shown in Figure 2C,
the dose–response effect of EGF proportionally increased with
the total number of cells per well. Such increase was consistent
with the HTRF signals reflecting the total ERK1/2 expressed in
the cells (Figure 2D). However, the HTRF signal resulting from
total ERK1/2 was independent of EGF concentration, validat-
ing the specificity of HTRF signals as a measure of the activated
ERK1/2 only (Figure 2D). Then, we examined the dose effect of
EGFR-mediated ERK1/2 activation in various cell lines: NIH-3T3
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FIGURE 5 | Dose–response analysis of GPCR-mediated
Phospho-ERK1/2 activation. Agonist-induced Phospho-ERK1/2 was
assessed using various GPCRs stably expressed in CHO cells: CB1 (A),
S1P5 (B), VPAC1 (C), EP2 (D), CXCR7 (E), V2R (F), and MOP3R (G).
Cells were stimulated for 10 min with increasing concentrations of each
GPCR-selective agonist as indicated before HTRF measurements were
performed using the one-plate protocol. The figures are representative of
three independent experiments performed in single points or duplicate.
mouse embryonic fibroblast (Figure 2E), SKOV3 human ovar-
ian carcinoma (Figure 2F), and HEK293 (Figure 2G). For this,
we used the one-plate protocol and cells were treated for 5 min
with increasing concentrations of EGF. Such cell lines display
large differences in the expression levels of EGFR per cell: 900,000
for A431 and 150,000 for SKOV3 (28), as well as 20,000 for
HEK293 (data not shown). As a result, the HTRF signals reflect-
ing ERK1/2 phosphorylation nicely increased to different extents
with the increasing concentrations of EGF, and with the expected
potencies (pEC50 values of 9.22± 0.11 for A431, 9.46± 0.06 for
NIH-3T3, 9.89± 0.10 for SKOV3, and 9.62± 0.05 for HEK293)
(37–39) regardless of the expression level of EGFR. Together, our
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FIGURE 6 | Inhibition of ERK1/2 pathway assessed by the Phospho-ERK
assay. CHO cells stably expressing MOP3R (A) and HEK293 cells transiently
expressing V2R (B), PAR1 (C), or NMUR2 (D) were used for the detection of
ERK1/2 phosphorylation upon cell stimulation with 2 nM of DAMGO (A),
100 nM of AVP (B), 1 U/ml of thrombin (C), or 30 nM of NmU-25 (D) for 5 min,
using 105 cells/well and the two-plate protocol. To assess the inhibition, cells
were first pre-treated either with CTOP (A) for 15 min or overnight with
200 ng/ml of PTX (B–D) before agonist stimulation and HTRF measurements.
The data are mean±SEM of three independent experiments performed in
duplicate.
data clearly demonstrate successful application of the Phospho-
ERK assay to assess RTK-mediated ERK1/2 signaling in various
cell models from human and mouse.
COMPARISON BETWEEN HTRF®-BASED ANDWESTERN BLOT-BASED
ERK1/2 ASSAYS
As mentioned above, the assessment of ERK1/2 activation by
western blot using an antibody recognizing the phosphorylated
forms of ERK1/2 represents the widely used method. First, we
performed a comparative study on A431 cells. The phosphoryla-
tion of ERK1/2 upon stimulation with 100 nM of EGF for 5 min
was measured on the same number of cells comparing the west-
ern blot and HTRF®-based assay (Phospho-ERK assay) with the
one-plate protocol. As shown in Figure 3A, the HTRF®-based
assay used to detect the phosphorylated from of ERK1/2 presents
a very good signal-to-noise ratio (S/N= 18). The Phospho-ERK
assay was substantially more sensitive than the western blot
assay, since ~400 cells were enough to start detecting specific
EGF-induced ERK1/2 phosphorylation using the HTRF®-based
assay while ~7500–15,000 cells were needed for the western blot
method (Figure 3A). Such a significant difference in the sensi-
tivity between the Phospho-ERK assay and western blot method
was also confirmed when the total ERK1/2 levels were quantified
in the different cell samples (Figure 3B). Indeed, the normalized
quantification of the intensities of western blot bands of the total
ERK1/2 clearly indicated that proteins were effectively detected at
1875–3750 cells while 234–468 cells per well were sufficient for
the specific HTRF signal reflecting the total ERK1/2 (Figure 3C)
showing a sensitivity factor of about 10-fold between the two
methods.
USE OF THE PHOSPHO-ERK ASSAY TO MONITOR GPCR-MEDIATED
ERK1/2 ACTIVATION
As stated above, it is now evident that GPCR activation can pro-
mote MAP kinase signaling, which has been shown to imply either
G protein-dependent and/or G protein-independent activation
pathways (4, 40, 41). Thus, we carried out a series of validation
experiments with the Phospho-ERK assay on various GPCRs cou-
pling to different heterotrimeric G proteins (Gs, Gi/o, Gq). We
assessed the kinetics of ERK1/2 phosphorylation mediated by two
GPCRs known to induce ERK1/2 activation, vasopressin 2 receptor
(V2R) (42), and protease-activated receptor 1 (PAR1) (43, 44). The
activation of V2R (Figure 4A) and PAR1 (Figure 4B), transiently
expressed in HEK293 cells, with 100 nM of AVP and 1 U/ml of
thrombin, respectively, induced a rapid increase in ERK1/2 phos-
phorylation that showed a sustained stimulation peak at 2–5 min
for V2R (Figure 4A) and 2–10 min for PAR1 (Figure 4B). The
activation of ERK1/2 was then followed by a slow decline to return
back to the basal level after ~30 min of stimulation. The data
obtained with PAR1 are in agreement with the previous obser-
vations in astrocytes using the western blot technique (44). These
kinetic profiles further demonstrate GPCRs activating the mito-
genic signaling pathways known to be mediated through either G
protein-dependent or -independent (i.e.,β-arrestin) pathways (41,
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45). However, many other molecular and cellular factors have been
reported to determine the duration and strength of ERK1/2 activa-
tion such as cell surface receptor density, expression of scaffolding
proteins, and the balance of intracellular kinases and phosphatases
(1, 7). Next, we extended our analysis to multiple other GPCRs
activated for 5 min with maximal dose (100 nM) of their respective
agonists using the one-plate protocol. This resulted in a substantial
and specific increase in the HTRF signals compared to mock cells,
with similar strength compared to the assay’s high control, thereby
validating the assay (Figure 4C). To further illustrate the specificity
of the GPCR agonist-induced HTRF signals, we tested the effect of
cross-stimulation with 100 nM of AVP and angiotensin II (AngII)
on the vasopressin V2 (V2R) and angiotensin II (AT1R) receptors
transiently expressed in HEK293FT cells. As expected, AVP but not
AngII specifically stimulated V2R-mediated ERK1/2 phosphoryla-
tion and vice versa AngII but not AVP specifically stimulated AT1R-
mediated ERK1/2 phosphorylation (Figure 4D). Neither agonist
promoted any ERK1/2 phosphorylation in mock-transfected cells.
DOSE–RESPONSE ANALYSIS OF GPCR-MEDIATED ERK1/2 ACTIVATION
We examined the dose-dependent effect of the agonists activating
various GPCRs stably expressed in CHO cells and using the two-
plate protocol (Figure 5). Stimulation of cells for 10 min with the
GPCR-selective agonists resulted in significant dose-dependent
increases in the HTRF signals to different extents. The dose–
response curves exhibited the expected potencies of the agonist-
receptor pairs, which are close to the nanomolar range. These
data clearly demonstrate a successful application of the Phospho-
ERK assay to assess the phosphorylation and activation of ERK1/2
mediated by GPCR activation regardless of the receptor’s G protein
coupling profile.
USE OF THE PHOSPHO-ERK ASSAY TO MONITOR INHIBITION OF
RECEPTOR-MEDIATED ERK1/2 SIGNALING
We studied the applicability of the Phospho-ERK assay for
investigating inhibitors of cell surface receptors with respect to
ERK1/2. For GPCRs, we used µ-opioid receptor 3 (MOP3R) sta-
bly expressed in CHO cells as a model, as this receptor has been
shown to activate ERK1/2 (46). These cells were treated with
the somatostatin peptide analog (d-Phe-Cys-Tyr-d-Trp-Orn-Thr-
Pen-Thr-NH2; CTOP), which has been described as a selective
antagonist of µ-opioid receptors (47). As shown in Figure 6A,
pre-treatment of cells for 15 min with increasing concentrations
of CTOP nicely inhibited the DAMGO-induced HTRF signal,
indicating the specific inhibition of ERK1/2 activation induced
by MOP3R. For EGFR, both the reversible and ATP-competitive
EGFR-selective inhibitor, Erlotinib (48) and the specific inhibitory
anti-EGFR monoclonal antibody, Cetuximab (49), nicely inhib-
ited the EGF-induced HTRF signal in a dose-dependent manner
with the expected potencies (50, 51). These data published on
the Cisbio website3 demonstrate the specificity of EGF-induced
HTRF signals, which reflects EGFR activation promoting ERK1/2
phosphorylation.
We then examined the involvement or not of different het-
erotrimeric G proteins in GPCR-mediated ERK1/2 pathways since
3http://www.htrf.com/phospho-erk-thr202tyr204-cellular-assay-kit
FIGURE 7 | Z ′-factor measurements for the Phospho-ERK assay. CHO
cells stably expressing the muscarinic receptor 1 (M1) were used for the
determination of Z ′-factor for the Phospho-ERK1/2 assay using the
Phospho-ERK assay one-plate protocol. Cells were stimulated or not with
1.33µM (EC80) (A) or 4µM (EC100) (B) of carbachol for 15 min and HTRF
signals were measured as described in Section “Materials and Methods.”
Solid lines show the means of the positive control (carbachol) and negative
control (vehicle). Broken lines display three standard deviations from the
mean of each data set [Adapted from the CisBio Bioassays website (see
text footnote 2) with permission].
GPCRs are known to couple to different classes of heterotrimeric
G proteins and to promote ERK1/2 via the activation of G
protein-dependent and/or G protein-independent pathways (41,
52). Therefore, we examined the effect of pertussis toxin (PTX)
blocking on GPCR-induced ERK1/2 phosphorylation using differ-
ent GPCRs having different G protein coupling profiles. We tested
V2R (mostly Gs) (53), PAR1 (Gi/o, Gq, and G12/13) (54), and neu-
romedin U receptor 2 (NMU2R; Gq and Gi/o) reported to activate
ERK1/2 (55), as well as MOP3R, which is coupled to PTX-sensitive
Gi/o proteins resulting in inhibition of adenylyl cyclase (56). As
shown in Figure 6B, PTX did not affect the kinetics of Phospho-
ERK1/2 mediated by V2R upon its stimulation with 100 nM of
AVP consistent with its PTX-insensitive Gs coupling and the
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previous study demonstrating ERK1/2 being activated by V2R
independently of heterotrimeric G protein signaling (42). In con-
trast, PTX treatment substantially inhibited the time-dependent
ERK1/2 activation mediated by PAR1 following its stimulation
with 1 U/ml of thrombin (Figure 6C). This observation is con-
sistent with a role of PTX-sensitive G protein (i.e., Gαi/o) (54).
However, the partial inhibition by PTX suggests a putative role of
another PTX-insensitive G protein (i.e., Gαq) and/or G protein-
independent pathway (i.e., β-arrestins) in PAR1-mediated activa-
tion of ERK1/2. For NMU2R, the ERK1/2 activation appears to be
primarily mediated by a PTX-sensitive G protein since the signal
peak observed at 5 min post-stimulation with 30 nM of NmU-25
was completely abolished by PTX (Figure 6D). Together, these data
clearly demonstrate the successful validation of the Phospho-ERK
assay to dissect the signaling pathways and the involvement of G
protein-dependent and -independent signaling leading to ERK1/2
activation.
POTENTIAL APPLICATION OF THE PHOSPHO-ERK ASSAY FOR
HIGH-THROUGHPUT SCREENING
In HTS assays, the Z ′-factor is often used as a performance indi-
cator for which an excess of 0.5 indicates high assay performance
(57). We determined a Z ′ value for the Phospho-ERK assay using
the muscarinic receptor 1 (M1) stably expressed in CHO cells and
stimulated with carbachol. The Z ′ value of 0.7 (Figure 7) demon-
strates the potential of Phospho-ERK for screening in a cell-based
assay system.
In conclusion, in addition to profiling receptors and their resul-
tant ERK1/2 signaling, the Phospho-ERK assay shows great poten-
tial for cell-based HTS. Thus, in combination with the IP-One
and cAMP assays (19, 23, 24), the Phospho-ERK assay com-
pletes the innovative panel of HTRF®-based assays dedicated to
dissecting and profiling cell surface receptor-mediated signaling
(22). This is particularly powerful as it facilitates investigation
of the spectrum of ligand-directed and biased signaling, with
the activation of ERK1/2 constituting one of the key signaling
pathways that has important physiological and pathophysiological
implications.
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